Table S1. Summary of cost and QALY parameters used in the model

| Parameter | Mean  | Distribution               |
|-----------|-------|----------------------------|
| **Treatment/Screening costs** |       |                            |
| Cervical cancer treatment    | £16,400 | Lognormal (SD: 10,000)     |
| Cytology (liquid-based)      | £58    | Normal (SD: 15)            |
| Colposcopy                   | £156   | Normal (SD: 39)            |
| Pre-cancerous lesion treatment | £378   | Normal (SD: 94)            |
| **Vaccine costs (per dose)** |       |                            |
| Quadrivalent vaccine         | £86.50 | Fixed (LHS not used)       |
| Administration               | £9.33  | Fixed (LHS not used)       |
| Vaccine wastage              | 0.1    | Fixed (LHS not used)       |
| **Quality of life weights**  |       |                            |
| Cervical cancer treatment    | 0.285  | Triangular (min:0.25, max: 0.32, mode: 0.285) |
| Post-cancer treatment        | 0.0305 | Triangular (min: 0.00682, max: 0.0542, mode: 0.0305) |
| **QALY loss per episode**    |       |                            |
| Positive cytology result     | 0.025  | Normal (SD: 0.00625)       |
| Positive CIN1 result         | 0.012  | Normal (SD: 0.003)         |
| Positive CIN2 result         | 0.007  | Normal (SD: 0.00175)       |
| Positive CIN3 result         | 0.054  | Normal (SD: 0.00135)       |
| Cervical cancer treatment time (years) | 0.116 | Lognormal (SD: 0.36)      |

Source: Jit M, Brisson M, Laprise JF, Choi YH. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015; 350: g7584.